HER2-positive Metastatic Breast Cancer Clinical Trial
Official title:
Phase II Study of Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab
Currently, data of the efficacy of trastuzumab plus pertuzumab and chemotherapy is limited in the HER2 positive metastatic breast cancer patients previously treated with trastuzumab during (neo)adjuvant and metastatic setting, and results are not consistent.The main purpose of this study is to evaluate the 6-month progression free survival(PFS) of trastuzumab(Henlius®) combined with Pertuzumab(Perjeta®) and Chemotherapy as first to third line therapy in Chinese patients with HER2 positive metastatic breast cancer who received trastuzumab previously.Primary Endpoint is 6-month Progression-free survival (PFS);Secondary Endpoint(s) include Progression-free survival (PFS) Overall Survival (OS);Objective Response Rate(ORR);
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06278870 -
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
|
Phase 3 | |
| Recruiting |
NCT04692831 -
Testing a New Imaging Agent to Identify Cancer
|
Phase 1 | |
| Recruiting |
NCT04385563 -
A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
|
Phase 3 | |
| Terminated |
NCT04778982 -
Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
|
||
| Active, not recruiting |
NCT03417544 -
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
|
Phase 2 | |
| Recruiting |
NCT04319757 -
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05583110 -
Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT06298084 -
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05650879 -
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT03979339 -
Feasibility of a New Technology for Isolating Circulating Tumour Cells
|
N/A | |
| Recruiting |
NCT05042791 -
A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases
|
Phase 2 | |
| Active, not recruiting |
NCT05555251 -
BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04602117 -
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT05959291 -
Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
|
N/A | |
| Recruiting |
NCT06299852 -
Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer
|
N/A | |
| Completed |
NCT06305702 -
Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer
|
||
| Completed |
NCT02605915 -
Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT05868226 -
PRE-I-SPY Phase I/Ib Oncology Platform Program
|
Phase 1 | |
| Recruiting |
NCT05800275 -
Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease
|
Phase 2 | |
| Recruiting |
NCT05036252 -
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
|